A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors
Clinical trial NCT05661578 · COMPLETED
Trial details
- NCT number
- NCT05661578
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-04
- Primary completion
- 2025-12-26
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.